Drugs / JY231 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06890065 | Mar 2025 → Dec 2027 expected | B-cell acute lymphoblastic leukemia | Shenzhen Genocury Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY231 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06890065 ↗ |
| Route | Intravenous | “subjects will receive an intravenous infusion of the JY231 preparation.” NCT06890065 ↗ |